MedTrace Logo

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

NCT01784978 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-10-02

No results posted yet for this study

Summary

The objective of this study is to assess the progression-free survival, of patients who receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a first line treatment followed by everolimus when progression occurs.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib

50 mg pd

DRUG

Everolimus

10 mg pd

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Pivotal S.L.

    collaborator INDUSTRY

  • Associació per a la Recerca Oncologica, Spain

    lead OTHER

Principal Investigators

  • Joaquim Bellmunt, MD/PhD · Associacio Per la Recerca Oncológica (APRO)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-12
Primary Completion
2017-05-08
Completion
2017-05-08

Countries

  • France
  • Greece
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01784978 on ClinicalTrials.gov